These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19864076)

  • 1. Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications.
    Zhang W; Hu R
    Med Hypotheses; 2010 Feb; 74(2):242-3. PubMed ID: 19864076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
    Baradaran N; Ahmadi H; Salem S; Lotfi M; Jahani Y; Baradaran N; Mehrsai AR; Pourmand G
    Prostate; 2009 Dec; 69(16):1744-50. PubMed ID: 19676082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States).
    Chan JM; Latini DM; Cowan J; Duchane J; Carroll PR
    Cancer Causes Control; 2005 Sep; 16(7):789-97. PubMed ID: 16132789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study.
    Li Q; Kuriyama S; Kakizaki M; Yan H; Sone T; Nagai M; Sugawara Y; Ohmori-Matsuda K; Hozawa A; Nishino Y; Tsuji I
    Cancer Causes Control; 2010 Jul; 21(7):1025-32. PubMed ID: 20228997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleotide-excision repair and prostate cancer risk.
    Lockett KL; Snowhite IV; Hu JJ
    Cancer Lett; 2005 Apr; 220(2):125-35. PubMed ID: 15766587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvascular permeability in diabetes and insulin resistance.
    Yuan SY; Breslin JW; Perrin R; Gaudreault N; Guo M; Kargozaran H; Wu MH
    Microcirculation; 2007; 14(4-5):363-73. PubMed ID: 17613808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications.
    Velicer CM; Dublin S; White E
    Prostate Cancer Prostatic Dis; 2007; 10(1):46-51. PubMed ID: 17033617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus.
    Quraishi I; Collins S; Pestaner JP; Harris T; Bagasra O
    Med Hypotheses; 2005; 65(5):887-92. PubMed ID: 16043303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of the complications of diabetes.
    Vinik AI; Vinik E
    Am J Manag Care; 2003 Mar; 9(3 Suppl):S63-80; quiz S81-4. PubMed ID: 12653455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
    Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
    Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
    Gong Z; Neuhouser ML; Goodman PJ; Albanes D; Chi C; Hsing AW; Lippman SM; Platz EA; Pollak MN; Thompson IM; Kristal AR
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1977-83. PubMed ID: 17035408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes: Microvascular ischemia of pancreatic islets?
    Tal MG
    Med Hypotheses; 2009 Sep; 73(3):357-8. PubMed ID: 19419817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome is associated with reduced risk of prostate cancer.
    Tande AJ; Platz EA; Folsom AR
    Am J Epidemiol; 2006 Dec; 164(11):1094-102. PubMed ID: 16968859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic microvascular complications: can patients at risk be identified? A review.
    Girach A; Manner D; Porta M
    Int J Clin Pract; 2006 Nov; 60(11):1471-83. PubMed ID: 17073842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of cruciferous vegetables and prostate cancer.
    Giovannucci E; Rimm EB; Liu Y; Stampfer MJ; Willett WC
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1403-9. PubMed ID: 14693729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.
    Jacobs EJ; Rodriguez C; Mondul AM; Connell CJ; Henley SJ; Calle EE; Thun MJ
    J Natl Cancer Inst; 2005 Jul; 97(13):975-80. PubMed ID: 15998950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.